Literature DB >> 30741369

Tactile Stimulation on Adulthood Modifies the HPA Axis, Neurotrophic Factors, and GFAP Signaling Reverting Depression-Like Behavior in Female Rats.

Kr Roversi1, Caren Tatiane de David Antoniazzi2, L H Milanesi1, H Z Rosa1, M Kronbauer1, D R Rossato3, T Duarte1, M M Duarte4, Marilise E Burger5.   

Abstract

Depression is a common psychiatric disease which pharmacological treatment relieves symptoms, but still far from ideal. Tactile stimulation (TS) has shown beneficial influences in neuropsychiatric disorders, but the mechanism of action is not clear. Here, we evaluated the TS influence when applied on adult female rats previously exposed to a reserpine-induced depression-like animal model. Immediately after reserpine model (1 mg/kg/mL, 1×/day, for 3 days), female Wistar rats were submitted to TS (15 min, 3×/day, for 8 days) or not (unhandled). Imipramine (10 mg/kg/mL) was used as positive control. After behavioral assessments, animals were euthanized to collect plasma and prefrontal cortex (PFC). Behavioral observations in the forced swimming test, splash test, and sucrose preference confirmed the reserpine-induced depression-like behavior, which was reversed by TS. Our findings showed that reserpine increased plasma levels of adrenocorticotropic hormone and corticosterone, decreased brain-derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B, and increased proBDNF immunoreactivity in the PFC, which were also reversed by TS. Moreover, TS reestablished glial fibrillary acidic protein and glucocorticoid receptor levels, decreased by reserpine in PFC, while glial cell line-derived neurotrophic factor was increased by TS per se. Our outcomes are showing that TS applied in adulthood exerts a beneficial influence in depression-like behaviors, modulating the HPA axis and regulating neurotrophic factors more effectively than imipramine. Based on this, our proposal is that TS, in the long term, could be considered a new therapeutic strategy for neuropsychiatric disorders improvement in adult life, which may represent an interesting contribution to conventional pharmacological treatment.

Entities:  

Keywords:  BDNF; Handling; Hypothalamus-pituitary-adrenal axis; Reserpine

Mesh:

Substances:

Year:  2019        PMID: 30741369     DOI: 10.1007/s12035-019-1522-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  83 in total

1.  Effects of tactile-kinesthetic stimulation in preterms: a controlled trial.

Authors:  S Mathai; A Fernandez; J Mondkar; W Kanbur
Journal:  Indian Pediatr       Date:  2001-10       Impact factor: 1.411

2.  Search for the presence of glucocorticoid receptors in dopaminergic neurons of rat ventral tegmental area and substantia nigra.

Authors:  A Czyrak; A Chocyk
Journal:  Pol J Pharmacol       Date:  2001 Nov-Dec

Review 3.  Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test.

Authors:  John F Cryan; Rita J Valentino; Irwin Lucki
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

Review 4.  The burden of severe depression: a review of diagnostic challenges and treatment alternatives.

Authors:  Charles B Nemeroff
Journal:  J Psychiatr Res       Date:  2006-07-25       Impact factor: 4.791

5.  Serotonergic cells of the rat raphe nuclei express mRNA of tyrosine kinase B (trkB), the high-affinity receptor for brain derived neurotrophic factor (BDNF).

Authors:  T R Madhav; Q Pei; T S Zetterström
Journal:  Brain Res Mol Brain Res       Date:  2001-09-10

6.  GDNF family ligands display distinct action profiles on cultured GABAergic and serotonergic neurons of rat ventral mesencephalon.

Authors:  Angélique Ducray; Sandra H Krebs; Benoît Schaller; Rolf W Seiler; Morten Meyer; Hans R Widmer
Journal:  Brain Res       Date:  2005-12-27       Impact factor: 3.252

7.  Suppression of GDNF production by MPSS treatment following spinal cord injury in the rat.

Authors:  Shojiro Nakashima; Yukihiro Matsuyama; Yimin Yu; Kazutoshi Kiuchi; Naoki Ishiguro
Journal:  Neuroreport       Date:  2004-10-25       Impact factor: 1.837

8.  Regulatory role of glucocorticoids and glucocorticoid receptor mRNA levels on tyrosine hydroxylase gene expression in the locus coeruleus during repeated immobilization stress.

Authors:  Shinya Makino; Mark A Smith; Philip W Gold
Journal:  Brain Res       Date:  2002-07-12       Impact factor: 3.252

9.  Interaction between estrogens and antidepressants in the forced swimming test in rats.

Authors:  Erika Estrada-Camarena; Alonso Fernández-Guasti; Carolina López-Rubalcava
Journal:  Psychopharmacology (Berl)       Date:  2004-01-17       Impact factor: 4.530

Review 10.  The glucocorticoid receptor: part of the solution or part of the problem?

Authors:  Carmine M Pariante
Journal:  J Psychopharmacol       Date:  2006-07       Impact factor: 4.153

View more
  4 in total

1.  Tactile Stimulation in Adult Rats Modulates Dopaminergic Molecular Parameters in the Nucleus accumbens Preventing Amphetamine Relapse.

Authors:  D R Rossato; H Z Rosa; J L O Rosa; L H Milanesi; V G Metz; L F D'Àvila; M E Burger
Journal:  Mol Neurobiol       Date:  2022-06-22       Impact factor: 5.682

2.  Neonatal Tactile Stimulation Downregulates Dendritic Spines in Layer V Pyramidal Neurons of the WAG/Rij Rat Somatosensory Cortex.

Authors:  Gul Ilbay; Aymen Balıkcı; Sibel Köktürk; Melda Yardımoglu Yılmaz; Nurbay Ates; Canan Baydemır; Sibel Balcı
Journal:  Neural Plast       Date:  2022-04-12       Impact factor: 3.144

3.  Targeting the Neuronal Activity of Prefrontal Cortex: New Directions for the Therapy of Depression.

Authors:  Xiao-Ting Zhou; Wen-Dai Bao; Dan Liu; Ling-Qiang Zhu
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

4.  Xiaoyaosan exerts antidepressant-like effects by regulating the functions of astrocytes and EAATs in the prefrontal cortex of mice.

Authors:  Yan Liu; Xiu-Fang Ding; Xin-Xing Wang; Xiao-Juan Zou; Xiao-Juan Li; Yue-Yun Liu; Jie Li; Xiu-Yun Qian; Jia-Xu Chen
Journal:  BMC Complement Altern Med       Date:  2019-08-14       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.